Nosocomial Infections - Pipeline Review, H2 2011

Document Sample
Nosocomial Infections - Pipeline Review, H2 2011 Powered By Docstoc
					Nosocomial Infections – Pipeline Review, H2 2011




         Nosocomial Infections - Pipeline Review, H2 2011
                                                                                          Reference Code: GMDHC1481IDB

                                                                                          Publication Date: October 2011




Nosocomial Infections – Pipeline Review, H2 2011                                                                 GMDHC1481IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Nosocomial Infections – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 4
      List of Figures .................................................................................................................................................................................................... 5
Introduction .............................................................................................................................................................................................................. 6
      Global Markets Direct Report Coverage ............................................................................................................................................................. 6
Nosocomial Infections Overview ............................................................................................................................................................................... 7
Therapeutics Development ....................................................................................................................................................................................... 8
      An Overview of Pipeline Products for Nosocomial Infections .............................................................................................................................. 8
Nosocomial Infections Therapeutics under Development by Companies .................................................................................................................10
Nosocomial Infections Therapeutics under Investigation by Universities/Institutes ...................................................................................................12
Late Stage Products ................................................................................................................................................................................................13
      Comparative Analysis .......................................................................................................................................................................................13
Mid Clinical Stage Products .....................................................................................................................................................................................14
      Comparative Analysis .......................................................................................................................................................................................14
Early Clinical Stage Products ..................................................................................................................................................................................15
      Comparative Analysis .......................................................................................................................................................................................15
Discovery and Pre-Clinical Stage Products..............................................................................................................................................................16
      Comparative Analysis .......................................................................................................................................................................................16
Nosocomial Infections Therapeutics - Products under Development by Companies ................................................................................................17
Nosocomial Infections Therapeutics - Products under Investigation by Universities/Institutes ..................................................................................18
Companies Involved in Nosocomial Infections Therapeutics Development ..............................................................................................................19
      Intercell AG .......................................................................................................................................................................................................19
      Theravance, Inc. ...............................................................................................................................................................................................19
      Immupharma Plc ...............................................................................................................................................................................................20
      Novacta Biosystems Limited .............................................................................................................................................................................20
      Priaxon AG .......................................................................................................................................................................................................21
      MAT Biopharma ................................................................................................................................................................................................21
      Integrated BioTherapeutics, Inc. ........................................................................................................................................................................22
      Trius Therapeutics, Inc. .....................................................................................................................................................................................22
Nosocomial Infections - Therapeutics Assessment ..................................................................................................................................................23
      Assessment by Monotherapy Products .............................................................................................................................................................23
      Assessment by Route of Administration ............................................................................................................................................................24
      Assessment by Molecule Type ..........................................................................................................................................................................26
Drug Profiles ...........................................................................................................................................................................................................28
      Arbelic - Drug Profile .........................................................................................................................................................................................28
            Product Description ....................................................................................................................................................................................28
            Mechanism of Action...................................................................................................................................................................................28
            R&D Progress .............................................................................................................................................................................................28
      NVB333 - Drug Profile.......................................................................................................................................................................................29
            Product Description ....................................................................................................................................................................................29
            Mechanism of Action...................................................................................................................................................................................29
            R&D Progress .............................................................................................................................................................................................29
      NVB302 - Drug Profile.......................................................................................................................................................................................30
            Product Description ....................................................................................................................................................................................30
            Mechanism of Action...................................................................................................................................................................................30
            R&D Progress .............................................................................................................................................................................................30
      IC43 - Drug Profile ............................................................................................................................................................................................31


Nosocomial Infections – Pipeline Review, H2 2011                                                                                                              GMDHC1481IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Nosocomial Infections – Pipeline Review, H2 2011


           Product Description ....................................................................................................................................................................................31
           Mechanism of Action...................................................................................................................................................................................31
           R&D Progress .............................................................................................................................................................................................31
     Colistin - Drug Profile ........................................................................................................................................................................................32
           Product Description ....................................................................................................................................................................................32
           Mechanism of Action...................................................................................................................................................................................32
           R&D Progress .............................................................................................................................................................................................32
     Acetylsalicylic Acid - Drug Profile ......................................................................................................................................................................33
           Product Description ....................................................................................................................................................................................33
           Mechanism of Action...................................................................................................................................................................................33
           R&D Progress .............................................................................................................................................................................................33
     Acetylsalicylic Acid - Drug Profile ......................................................................................................................................................................34
           Product Description ....................................................................................................................................................................................34
           Mechanism of Action...................................................................................................................................................................................34
           R&D Progress .............................................................................................................................................................................................34
     Acetylsalicylic Acid - Drug Profile ......................................................................................................................................................................36
           Product Description ................................................................................................................................................
				
DOCUMENT INFO
Description: Nosocomial Infections - Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Nosocomial Infections - Pipeline Review, H2 2011', provides an overview of the Nosocomial Infections therapeutic pipeline. This report provides information on the therapeutic development for Nosocomial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nosocomial Infections. 'Nosocomial Infections - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Nosocomial Infections. - A review of the Nosocomial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Nosocomial Infections pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Nosocomial Infections. - Identify emerging players with potentially stro
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries